Introduction {#s0005}
============

Cardiovascular disease (CVD) remains a global killer affecting every ethnic group and accounts for approximately one-third of all deaths ([www.who.int](http://www.who.int){#ir0005}, [www.heartstats.org](http://www.heartstats.org){#ir0010}). Over the past few decades there have been major advances in the treatment of patients presenting with a cardiovascular event, including primary percutaneous coronary intervention (PPCI) with stent insertion in acute myocardial infarction (AMI) [@bib21] and rapid thrombolysis with tissue plasminogen activator (tPA) poststroke [@bib49]. This first line treatment coupled with effective secondary prevention using aspirin and other antiplatelet drugs, such as prasugrel [@bib54], have made substantial reductions in both mortality and morbidity. However, progress with respect to primary prevention of atherothrombotic events, despite considerable reductions already achieved through changes in lifestyle factors, remains an issue. Strong support for population approaches to prevention exist as articulated in the recent "European Guidelines on Cardiovascular Disease Prevention" [@bib47]. Until recently it was thought that aspirin offered an effective option, and its use was routinely recommended in the primary prevention of coronary heart disease and perhaps to a lesser extent in stroke [@bib1; @bib2; @bib33; @bib34]. However, recent meta-analyses [@bib6] and population studies [@bib13] indicate serious bleeding risks with aspirin, that in many cohorts outweigh the potential benefits, suggesting that alternatives with a more moderate antiplatelet profile might be of some value. The use of "statins" in primary prevention has received substantial support as also has the concept, first mooted by Wald and Law in 2003 [@bib48], of a cardiovascular *polypill*. However, the medicalisation of "healthy" individuals, noncompliance, and cost-effectiveness remain significant hurdles and uncertainties. Such issues have fuelled desires to better harness the beneficial and potentially antithrombotic effects of diets rich in fruit and vegetables [@bib16; @bib17]. This focus in part stems from the view that dietary interventions may be more acceptable and achievable for many individuals.

In this regard there has been growing interest in the possibility that dietary nitrate may underlie some of the beneficial effects of healthy diets. Inorganic nitrate is found in vegetables and is especially abundant in green-leafy vegetables and beetroot (*Beta vulgaris*). Small-scale clinical studies demonstrate that orally ingested inorganic nitrate is sequentially bioactivated within the enterosalivary circuit to inorganic nitrite (NO~2~^-^) [@bib20; @bib22; @bib52]. Dietary nitrate is rapidly absorbed across the upper intestine to enter the circulation. While the majority of this nitrate is eventually excreted in the urine, ∼25% is actively extracted by the salivary glands and then secreted into the saliva where it comes into close contact with facultative bacteria expressing nitrate reductases [@bib46] that have colonized the dorsal surface of the tongue. These bacteria reduce nitrate to nitrite that is then swallowed. Evidence suggests that at least some of this swallowed nitrite then appears within the circulation where it is converted to NO: a reaction thought to be facilitated by a number of enzyme-dependent and independent nitrite reductase pathways [@bib50]. This nitrite-derived NO, in turn, exerts a number of beneficial effects within the circulation, most notably that administration of dietary nitrate or nitrate supplementation, via reduction to nitrite, results in NO-mediated vasodilatation and decreases in blood pressure (BP) [@bib19; @bib22; @bib52]. Interestingly, post hoc analysis in one BP study also suggested that while females appeared to express a superior capacity to generate bioactive nitrite through this pathway that the activity of the nitrite generated was greater in males than in females [@bib19].

There is also some suggestion that dietary nitrate, via nitrite as an intermediate, may repress platelet reactivity. We have previously shown that consumption of dietary nitrate (as beetroot juice) attenuates *ex vivo* stimulated platelet aggregation; an effect that was lost if the oral conversion of nitrate to nitrite was prevented [@bib52], thereby preventing elevations of systemic nitrite levels. However, whether inorganic nitrate was responsible for this effect, whether NO was the underlying mediator of this response, and whether sex differences occurred in the effects of nitrate on platelet reactivity and the mammalian nitrite reductase pathways that might be involved in these effects remain uncertain. We have conducted clinical studies in healthy volunteers to interrogate these unknowns.

Methods {#s0010}
=======

Volunteers {#s0015}
----------

The studies were peer-reviewed by the institutional review board and were granted full ethics approval by The London Stanmore Research Ethics Committee (11/LO/0715). Informed, written consent was taken after satisfying the inclusion criteria. Volunteers were included if they fulfilled the following Inclusion criteria: 18--45 years of age, body mass index (BMI) of 18--40 kg/m^2^, and no systemic medication (other than the oral contraceptive pill). Volunteers adhered to a low nitrate diet and refrained from caffeine consumption and strenuous exercise the day before and the day of the respective study, and were fasted overnight before all study visits.

Investigation of the effect of dietary nitrate ingestion (beetroot juice) on platelet aggregation assessed ex vivo using light transmission aggregometry (LTA) {#s0020}
--------------------------------------------------------------------------------------------------------------------------------------------------------------

In a single-blind (investigator blind), randomised, placebo-controlled crossover study, male (*n*=12) and female (*n*=12) volunteers received dietary nitrate (as beetroot juice giving a nitrate dose: 3.1±0.35 mmol equivalent to approximately 190 mg) or matched-volume of low nitrate-containing water (Zepbrook Ltd., London, UK) placebo control, on two separate occasions, at least 7 to 28 days apart. For LTA, blood was collected into a 60 ml syringe preprepared with 3.2% sodium citrate through a 19 gauge butterfly needle and then immediately centrifuged (170*g*, 21 °C, 15 min) to generate platelet rich plasma (PRP) that was stored at 37 °C and used within 30 min. Blood was sequentially centrifuged (170*g*, 21 °C, 15 min, and then 15,000*g*, 21 °C, 2 min) to generate PRP and platelet-poor plasma (PPP), respectively. PRP was taken as equivalent to 0% aggregation and PPP was taken as equivalent to 100% aggregation, respectively. Platelet aggregation in response to adenosine diphosphate (ADP) (0.1--30 µmol/L), collagen (0.1--3 µg/ml), and epinephrine (0.001--100 µmol/L) was measured using a 96-well plate light transmission assay over 16 min, as previously described [@bib3]. For comparisons between groups and treatments the AUC of percentage aggregation response over 16 min was used. All measures were performed at baseline and at 3 h post intervention. This 3 h time point was selected in view of our previous findings demonstrating that circulating levels of nitrite, and the associated bioactivity, peak 3 h post nitrate ingestion [@bib52].

Assessment of the in vitro effects of nitrite on platelet aggregation {#s0025}
---------------------------------------------------------------------

Blood collected from healthy male volunteers (*n*=6--8) was incubated (10--30 min, 37 °C) with potassium nitrite (KNO~2~, 0.1--3 μmol/L), spermine-NONOate (Sper-NO; 1--10 μmol/L), or phosphate-buffered saline (PBS, as control). Platelet aggregation was assessed in response to ADP (0.1--10 µmol/L) and collagen (0.1--30 µg/ml) in PRP by LTA.

To assess the effect of nitrite on platelet aggregation in whole blood, blood was collected and incubated with nitrite for 10 min prior to assessment of aggregation in response to ADP or collagen using impedance aggregometry (*n*=12--15 males). In a separate series of experiments the effects of Sper-NO (1--10 μmol/L) on ADP-induced aggregation of whole blood were determined (*n*=5 males, *n*=5 females). An aliquot of blood was collected from each volunteer for *in vitro* incubation with nitrite (1 µmol/L, 10 min, 37 °C) followed by isolation of a platelet pellet for determination of cyclic guanosine monophosphate (cGMP) levels using a commercially available ELISA. In addition, a separate aliquot of blood was collected for erythrocyte isolation (*n*=7 males; *n*=5 females) and assessment of nitrite reductase activity using gas phase ozone chemiluminescence as previously described [@bib51].

Investigation of the effects of inorganic nitrate supplementation (KNO~3~ capsules) on whole blood platelet aggregation assessed ex vivo {#s0030}
----------------------------------------------------------------------------------------------------------------------------------------

In a double blind, randomised, placebo controlled crossover study male (*n*=12) and female (*n*=13) volunteers received either 8 mmol potassium nitrate (KNO~3~, Martindale Pharmaceuticals, Ipswich, UK, equivalent to 496 mg of nitrate) or matched potassium chloride (KCl, Martindale Pharmaceuticals, Ipswich, UK) placebo control, and returned for the cross-over limb between 7 and 28 days later. Capsules were consumed with 2 slices of dry wholemeal toast and 250 ml low-nitrate-containing water (Zepbrook Ltd., London, UK). Blood, urine, and saliva were collected for analysis of \[nitrate\] and \[nitrite\] and blood was separately collected for determination of P-selectin expression under unstimulated conditions. Platelet aggregation was assessed in whole blood in response to ADP (10 μmol/L), collagen (3 μg/ml), epinephrine (10 µmol/L), and PBS (as control) using an impedance aggregometer (MultiplateRanalyzer, Dyabyte Medical, Germany) measured over a 6 min period. Aggregation is quantified as AUC giving a measure of total resistance Ω^\*^time. Briefly 300 µL of citrated whole blood was added to 300 µL of normal saline with 3 mmol/L CaCl~2~ (Sigma, UK) and equilibrated with constant magnetic stirring for 3 min prior to addition of agonist and platelet aggregation measurement. For the incubation of whole blood with nitrite following a 3 min equilibration period, the relevant concentration of potassium nitrite was added and a further 10 min incubation period ensued prior to addition of aggregating agonist and measurement of platelet aggregation. All measures were performed at baseline and at 3 h.

Blood pressure measurement {#s0035}
--------------------------

Blood pressure was measured at baseline to confirm healthy volunteer status and effective randomisation. An Omron 705IT was used for all BP measurements while participants were seated and readings were performed in triplicate according to established guidelines [@bib53]. Laminated coverings were used for the machine and the printer so that both investigators and participants were blinded to the readings. The means of the 2nd and 3rd readings were used to calculate the final BP measurement.

Blood sampling {#s0040}
--------------

Blood was collected into either 1.8 mg EDTA per ml of blood (for NO~*x*~), 3.2% buffered sodium citrate (for aggregation assays), or 0.1 mmol/L 3-isobutyl-1-methylxanthine (IBMX) (for cGMP assay) containing vacutainers (BD) through a 21-gauge butterfly needle inserted into an antecubital vein. For the generation of platelet-rich plasma (PRP), citrated blood was immediately centrifuged (170*g* at 21 °C for 15 min) and PRP separated, stored at 37 °C, and used within 30 min. For measurement of NO~x~ levels, blood samples were centrifuged immediately (1300*g*, 4 °C, 10 min) and the supernatant was collected and stored at -80 °C pending analysis by ozone chemiluminescence.

Urine and saliva sampling {#s0045}
-------------------------

Mid-stream urine samples were collected into sterile pots and an aliquot was stored at -80 °C pending analysis by ozone chemiluminescence. Unstimulated saliva was collected into sterile Eppendorfs and centrifuged (14,000*g*, 4 °C, 10 min) and the supernatant was stored at −80 °C pending analysis by ozone chemiluminescence.

Ozone chemiluminescence {#s0050}
-----------------------

Briefly, to determine total nitrate and nitrite levels (collectively termed \[NO~x~\]), samples were added to 0.1 mmol/L vanadium (III) chloride in 1 mmol/L hydrochloric acid refluxing at 95 °C under nitrogen. Nitrite concentrations were determined by addition of samples to 0.09 mmol/L potassium iodide in glacial acetic acid under nitrogen at room temperature. \[Nitrate\] were calculated by subtraction of \[nitrite\] from \[NO~*x*~\] as previously described. [@bib14]

Measurement of platelet cGMP {#s0055}
----------------------------

For assessment of platelet cGMP following in vivo interventions blood (12 ml) was collected into 3 citrated tubes via the same puncture and 0.1 mmol/L IBMX (Sigma, UK) added. This blood was immediately centrifuged (170*g*, 15 min, 21 °C) to generate PRP that was then further centrifuged (1800*g*, 10 min, 4 °C) to obtain a platelet pellet and PPP. Both were then stored at −80 °C pending cGMP measurement. For assessment of the effects of the in vitro effects of nitrite on platelet cGMP, blood was collected as above and immediately incubated with nitrite at 37 °C for 10 min. Following this PRP and then a platelet pellet were generated and then stored at −80 °C pending cGMP measurement. Platelet cGMP was measured using an ELISA (GE Healthcare, Amersham) according to the manufacturer\'s instructions.

P-selectin expression {#s0060}
---------------------

Two-colour whole blood flow cytometry was used to measure platelet P-selectin using a modification of previously published protocols and recommendations [@bib41]. Whole blood was collected from individuals prior to and following ingestion of nitrate or placebo capsules. Samples were immediately incubated with selective antibodies, at room temperature for 20 min, and then fixed using 1% paraformaldehyde (Sigma, UK), stored at 4 °C and analysed 2 h after completion of each study visit using a Becton Dickinson FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA). The platelet population was identified preliminarily based on forward and side scatter properties, then further delineated via labeling with CD42b monoclonal antibody conjugated to allophycocyanin (APC). Gates were used to isolate this population, and CD62 (P-selectin) monoclonal antibody conjugated to (fluoroscenisothiocyanate) FITC was used to determine P-selectin expression. Populations were further confirmed by use of antibody negative isotypes to P-selectin and CD42b. All samples were run in duplicate. 10,000 platelets were acquired in the CD42b region, and results were expressed as the percentage of platelets positive for P-selectin.

Erythrocyte nitrite reductase assay {#s0065}
-----------------------------------

For the measurement of the nitrite reductase activity of tissue and erythrocyte samples gas phase chemiluminescence was used. Experiments were performed in a sealed 10-ml glass reaction chamber containing citric acid/Na₂HPO₄ buffer at pH 7.4 (physiological levels) or pH 6.8 (representing acidosis), and KNO~2~ (10--300 µmol/L) in a total volume of 1 ml. This solution was bubbled with nitrogen gas (100%) by means of an NO scrubbing air filter (Sievers, Boulder, CO, USA). The headspace NO concentration was measured in parts per billion by continuous sampling for ozone chemiluminescence (Sievers 280 A nitric oxide analyzer). The impact of biological tissue samples on NO production from nitrite, was determined by the addition of washed human RBCs from healthy human volunteers and measurement of NO over 2 min, calculating the rate of NO production (pmol per g per s) from the area under the curve.

Statistical analysis {#s0070}
--------------------

The data were analysed using Graphpad Prism software version 5. All data are expressed as mean±SEM. Data for LTA aggregometry represent the area under the curve (over 16 min)^\*^% platelet aggregation and are reported in arbitrary units, presented in concentration--response curves and were analysed using repeated-measures two-way ANOVA and Bonferroni post hoc tests. Erythrocytic nitrite reductase activity was analysed by two-way repeated-measures ANOVA. Nitrite incubation whole blood aggregometry data were analysed using one-way ANOVA and Dunnett\'s post hoc test compared to control (PBS). Systemic NO~x~ levels were analysed using one-way ANOVA and Bonferroni post hoc tests. For comparison of all other data paired Student\'s *t* tests were used. Values of *P*\<0.05 were considered significant.

Results {#s0075}
=======

All interventions were tolerated without adverse effects.

Dietary nitrate treatment attenuates ex vivo sensitivity of platelets to ADP {#s0080}
----------------------------------------------------------------------------

There were no significant differences in the demographics of healthy volunteers between visits ([Table 1](#t0005){ref-type="table"}).

In both male ([Fig. 1](#f0005){ref-type="fig"}) and female ([Fig. 2](#f0010){ref-type="fig"}) volunteers, dietary nitrate administration, in the form of beetroot juice, caused a significant rise in plasma \[nitrite\] and \[nitrate\]. *Ex vivo* assessment of platelet reactivity using LTA demonstrated concentration-dependent aggregation of platelets isolated from either male or female volunteers in response to collagen, ADP, and epinephrine ([Figs. 1 and 2](#f0005 f0010){ref-type="fig"}). Importantly, the concentration--response curves to both ADP and collagen, but not epinephrine, were significantly suppressed following dietary nitrate treatment in males ([Fig. 1](#f0005){ref-type="fig"}) but not females ([Fig. 2](#f0010){ref-type="fig"}). The placebo had no effect on platelet responses to any aggregating stimuli in either sex ([Figs. 1 and 2](#f0005 f0010){ref-type="fig"}).

In vitro incubation of platelets with nitrite does not alter platelet reactivity {#s0085}
--------------------------------------------------------------------------------

We next investigated whether the effects of dietary nitrate in male volunteers were related to a direct effect of nitrite on circulating platelets. Nitrite treatment did not alter the aggregating response to either ADP or collagen of PRP collected from untreated healthy male volunteers following a 30 min ([Fig. 3](#f0015){ref-type="fig"}A and B) or a 10 min pretreatment period ([Fig. 3](#f0015){ref-type="fig"}E and F). In contrast, prior incubation of platelets with Sper-NO caused a concentration-dependent attenuation of platelet aggregation ([Fig. 3](#f0015){ref-type="fig"}C, D, G, and H).

In vitro incubation of whole blood with nitrite attenuates platelet aggregation responses to ADP {#s0090}
------------------------------------------------------------------------------------------------

To investigate the possibility that nitrite bioactivity might be dependent on the presence of erythrocytes (a previously identified important site for nitrite conversion to NO within the circulation [@bib11]) we investigated the effect of incubation *in vitro* of whole blood, collected from male volunteers, with nitrite and subsequent sensitivity to platelet aggregating stimuli using whole blood impedance aggregometry. Nitrite incubation (KNO~2~, 10 min) caused a modest (maximum effect 27±8% inhibition) concentration-dependent reduction in platelet aggregation in response to ADP ([Fig. 4](#f0020){ref-type="fig"}A) and to a lesser extent collagen ([Fig. 4](#f0020){ref-type="fig"}B), although the latter did not reach statistical significance. Nitrite treatment had no effect on epinephrine-induced aggregation responses ([Fig. 4](#f0020){ref-type="fig"}C). Incubation with an equivalent salt solution control of KCL had no significant effect on responses to ADP (PBS 42±5.1 AU, 0.3 µmol/L 42.1±3.9 AU, 1 µmol/L 35±4.9 AU, 3 µmol/L 35.4±7.1 AU, *n*=5 for each). This effect of nitrite was associated with a near doubling of platelet cGMP levels ([Fig. 4](#f0020){ref-type="fig"}D). In contrast, nitrite did not alter responses of whole blood collected from female healthy volunteers to ADP and nitrite treatment was not associated with any elevation of platelet cGMP levels ([Fig. 4](#f0020){ref-type="fig"}E and F). In support of a reduced sensitivity of females to NO, Sper-NO caused concentration-dependent attenuation of platelet aggregation in response to ADP that was significantly reduced in females compared to males ([Table 2](#t0010){ref-type="table"})

Inorganic nitrate supplementation attenuates sensitivity of platelets to ADP and collagen in males only {#s0095}
-------------------------------------------------------------------------------------------------------

There were no significant differences in the demographics of healthy volunteers between visits ([Table 3](#t0015){ref-type="table"}). Of the females recruited for this study 6 were taking the contraceptive pill and 7 were not. Following KNO~3~ supplementation there was significant elevation in plasma, salivary, and urinary \[nitrate\] and \[nitrite\] in both male ([Fig. 5](#f0025){ref-type="fig"}) and female ([Fig. 6](#f0030){ref-type="fig"}) healthy volunteers, an effect not seen following KCl ingestion. In male volunteers these elevations were associated with a significant suppression of ADP ([Fig. 7](#f0035){ref-type="fig"}A and B) but not epinephrine-induced aggregatory response ([Fig. 7](#f0035){ref-type="fig"}C and D). In contrast, despite elevations in systemic \[nitrite\] and \[nitrate\] following KNO~3~ ingestion in female volunteers, no change in *ex vivo* platelet reactivity was demonstrated ([Fig. 7](#f0035){ref-type="fig"}E--H).

Suppression of platelet aggregation with dietary nitrate is associated with significant increase in platelet cGMP and suppression of P-selectin exposure {#s0100}
--------------------------------------------------------------------------------------------------------------------------------------------------------

In males, attenuation of *ex vivo* platelet reactivity following inorganic nitrate ingestion was associated with a doubling of platelet cGMP levels and a significant suppression of P-selectin expression ([Fig. 8](#f0040){ref-type="fig"}). Neither KNO~3~ or KCl ingestion affected platelet number in either males or females ([Fig. 8](#f0040){ref-type="fig"}A and E). In contrast, the lack of effect of inorganic nitrate consumption in females was associated with an absence of any rise in platelet cGMP levels and no changes in P-selectin expression ([Fig. 8](#f0040){ref-type="fig"}F--H). There were no differences in P-selectin mean fluorescence intensity between the groups (data not shown). The differences in the functional effects of oral nitrate ingestion between the sexes is unlikely to be due to differences in the nitrite reductase potential of erythrocytes since activity, assessed in vitro, at both pH 7.4 and 6.8 (optimal conditions for nitrite reduction) was identical ([Fig. 8](#f0040){ref-type="fig"}I and J).

Discussion {#s0105}
==========

Dietary (inorganic) nitrate may underpin the cardioprotective effects offered by fruit- and vegetable-rich diets [@bib16; @bib17; @bib20]. In support of this possibility, recent studies in healthy volunteers have shown a range of beneficial effects of acute administration of a dietary nitrate load [@bib52] or inorganic nitrate supplementation [@bib19; @bib22; @bib23] on the cardiovascular system including some suggestion of reduced platelet reactivity [@bib38; @bib52]. In the present study we demonstrate a modest antiplatelet effect of both dietary and inorganic nitrate supplementation in male but not female healthy volunteers. This effect in males is dependent on elevation of circulating nitrite followed by reduction of nitrite to NO, in part, at the level of the erythrocyte. In turn this NO suppresses platelet reactivity by elevation of cGMP. Our results also suggest that while the enterosalivary circuit and nitrite reductive pathways are intact in females, the antiplatelet effect is absent due to an absence of platelet cGMP increase. These findings suggest that dietary nitrate or inorganic nitrate supplementation may prove useful in providing a modest reduction of platelet activity either in primary prevention or as an adjunct to antiplatelet therapies in secondary prevention of atherothrombotic events. Moreover, our observations describe a novel sexual dimorphism that may help to better understand the sex differences evident in thrombotic potential in humans.

Inorganic nitrate administration caused a significant rise in both circulating nitrate, and consequently nitrite levels, whether administered in a dietary form or via inorganic nitrate supplementation. These changes in NO~x~ are similar to those demonstrated in healthy volunteers previously [@bib5; @bib19; @bib52]. It is accepted that, following its ingestion, inorganic nitrate is rapidly absorbed across the intestine and then either excreted by the kidneys or concentrated in the salivary glands, where in the case of the latter, it is secreted into the saliva [@bib46]. Our results demonstrate clear evidence of this pathway occurring in the healthy volunteers recruited into this clinical study. Within the oral cavity approximately two-thirds of inorganic nitrate is thought to be converted to nitrite by bacterial nitrate reductases [@bib18; @bib43; @bib46; @bib52]: a view likewise supported by our findings herein. This nitrite, once swallowed, enters the circulation with levels peaking at approximately 3 h following nitrate ingestion [@bib19; @bib52]. Importantly, the biological effects of inorganic nitrate ingestion correlate directly with the levels of nitrite in the circulation, peak simultaneously with the peak in circulating nitrite levels, and are thought to be due to the conversion of this nitrite to NO within the circulation [@bib19]. It was on this basis that all assessments of platelet function in the studies described herein were conducted 3 h following nitrate ingestion in order to observe the maximum possible effects.

We have demonstrated that the rise in circulating nitrite levels following either dietary nitrate ingestion or following inorganic nitrate supplementation was associated with a reduction in *ex vivo* platelet aggregation induced by either ADP or collagen using two distinct methods of assessment of platelet aggregation. Importantly, however, we found no effect on responses to the weak platelet activator epinephrine. Both ADP and collagen, while activating distinct receptors (P2Y1/P2Y12 and GPVI) and molecular pathways within the platelet, trigger a number of common phenomena implicated in platelet activation, including platelet granule secretion, thromboxane A~2~ release, and platelet aggregation events also commonly associated with increases in phosholipase C and phosphoinositide-3-kinase activity (see review [@bib25]). In contrast, epinephrine alters platelet reactivity by binding to α~2~-receptors coupled to Gi resulting in a reduction in intracellular cAMP levels. It has been suggested that per se epinephrine exerts little change in platelet response; however, when present in combination with other stronger activating stimuli such as ADP or histamine, α~2~-receptor activation enhances the stimulatory effect of the agonist [@bib7; @bib40]. Since epinephrine was not used in combination with other agonists this may underlie the absence in effect of inorganic nitrate on responses seen but also suggests that nitrate acts to suppress pathways implicated in platelet activation commonly associated with stronger stimuli.

It is likely that the repressive effects of inorganic nitrate on platelet reactivity are due to the formation and activity of NO in vivo. NO is a potent inhibitor of platelet function and basal NO generation is thought to play a crucial role in suppressing platelet reactivity in physiology [@bib26]. This activity of NO has been attributed, primarily, to activation of sGC and consequent elevation of platelet cGMP levels [@bib12; @bib30; @bib35; @bib39]. Although, there is also some suggestion that there may be sGC-independent effects of NO and NO donor drugs on platelets [@bib27; @bib32; @bib42; @bib55] and also controversially prostimulatory effects of the NO-sGC-cGMP pathway in platelets [@bib28; @bib45; @bib55]. More recently both of these possibilities have been challenged by demonstration of an absence of any anti- or indeed prostimulatory platelet effects of NO in mice lacking the β~1~ subunit of sGC [@bib12] or in mice with selective deletion of platelet sGC [@bib39]. Although, in contrast using the same platelet-specific mice evidence for a stimulatory effect of NO-induced cGMP has also been proffered [@bib55]. Nevertheless, irrespective of this controversy, our studies support an inhibitory role for the NO-sGC-cGMP pathway in platelets. Indeed, we show that inorganic nitrate ingestion in males elevates platelet cGMP levels implicating NO in the antiaggregatory effects. This effect likely underlies the beneficial effects since in females where no change in platelet reactivity was evident there was likewise no change in platelet cGMP levels.

The exact mechanisms involved in cGMP-induced suppression of platelet reactivity in the present study are uncertain. It has been suggested that elevation of cGMP in platelets results in PKG activation and consequent phosphorylation of a range of proteins that influence platelet function including inositol triphosphate receptors and phosphodiesterase 5 to name just two (see review [@bib15]). Irrespective of the exact molecular pathways involved, NO has been shown to cause a number of phenomena in platelets that would ultimately result in decreased activity including reduced granule secretion [@bib8; @bib29] and platelet adhesion [@bib36]: phenomena shown to be both cGMP dependent [@bib29; @bib37] and independent [@bib27; @bib31]. As an index of both of these characteristics we measured P-selectin expression and demonstrated that, in males treated with inorganic nitrate, unstimulated platelet P-selectin expression was suppressed and accordingly in females where cGMP was not changed no difference in P-selectin expression was evident.

The conversion of nitrite to NO within the circulation is thought to be facilitated by a number of distinct nitrite reductases that have been localised to either the erythrocyte or the blood vessel wall. To determine whether the platelet itself might be the site of nitrite reduction we investigated the effects of incubation of purified platelets with nitrite, at similar concentrations to those achieved following oral inorganic nitrate ingestion (i.e., 0.1--3 µmol/L), prior to assessment of aggregation using LTA. Our data show no effect of nitrite when incubated with platelets for 10 or 30 min despite clear evidence of sensitivity to NO, demonstrated using the NO donor Sper-NO. These observations are in agreement with recent studies testing similar concentrations of nitrite with human PRP demonstrating no effect of nitrite on ADP or collagen-induced aggregation [@bib44] and suggest that nitrite has no direct effect on platelets. In contrast, there are some suggestions that nitrite exerts direct inhibitory effects on platelets; however, the *in vivo* relevance of these observations are uncertain since the effects of nitrite were achieved with concentrations 10--100 times above that found circulating *in vivo* [@bib4; @bib24]. Thus, in agreement with recently published observations [@bib44], our findings intimate that while physiological concentrations of nitrite *in vivo* exert antiplatelet effects this is not due to its conversion to NO at the platelet itself.

To determine whether the erythrocyte might be the site of nitrite conversion within the circulation we assessed the effects of nitrite incubation on platelet aggregation in whole blood. Our data demonstrate that *in vitro* nitrite causes moderate concentration-dependent inhibition of platelet aggregation in response to ADP when incubated with whole blood collected from healthy male volunteers. This effect of nitrite was likely due to its conversion to NO since it was associated with elevations in platelet cGMP levels. It is therefore probable that in vivo nitrite reduction occurs, at least in part, at the erythrocyte. Indeed, there are several reports demonstrating erythrocytic nitrite reduction [@bib11; @bib51]. However, whether the erythrocyte accounts for all of the nitrite reduction occurring in vivo that underlies the reduced platelet sensitivity is uncertain. The exact nitrite reductase that might be involved in this effect is not certain. Recent *in vitro* studies suggest that deoxyhemoglobin might be the nitrite reductase on erythrocytes influencing platelet function since reductions in oxygen tension associated with increases in deoxyhemoglobin levels resulted in improved nitrite bioactivity [@bib44]. Whether this might be the pathway involved in our study is uncertain and warrants investigation.

Our studies also suggest that the pathways for NO bioactivity within the circulation are different between the sexes. More specifically, our data imply that the NO-sGC-cGMP pathway in platelets is impaired in females compared to males, resulting in a reduction of the antiplatelet effect of nitrite-derived NO in females. This difference in activity was not due to differences in the capacity to reduce nitrite to NO since the nitrite reductase activity of erythrocytes assessed ex vivo was identical between the sexes under varying pH conditions and nitrite concentrations. We suggest that the differences in bioactivity relate to a reduced sGC activity in females compared to males. Such a proposal is supported by our data demonstrating a reduced sensitivity of female blood to NO donors as well as an absence of effect of both dietary nitrate and in vitro nitrite administration on platelet function in women. Accordingly, a number of recent preclinical studies indicate a greater role for the NO-sGC-cGMP pathway in vascular reactivity in males compared to females. Indeed, while male sGC~α1~ knockout mice are hypertensive, female knockouts are not [@bib9]. In addition, our own recent investigations suggest that while sGC activators cause potent vasodilatation and decreases in BP in male mice, the activity is much reduced in females, an effect reflecting reduced sGC expression [@bib10]. Our observations shown herein suggest that this phenomenon translates to humans, although further molecular investigations are required to confirm this possibility.

Conclusions {#s0110}
===========

Thus, inorganic nitrate ingestion, whether taken via the diet or through supplementation, causes a modest decrease in platelet reactivity in healthy males but not females. This effect in males is associated with elevations of circulating nitrite resulting in NO-induced elevations of platelet cGMP, an effect that is absent in females and likely underlying the lack of responsiveness in terms of platelet activity in females. The effects of inorganic nitrate on platelet activity may offer potential in the therapeutics of cardiovascular disease in secondary prevention, as an adjunct to current antiplatelet therapies to prevent atherothrombotic complications. However, it is possible that the greatest potential of dietary nitrate may lie in primary prevention. The modest antiplatelet activity of such a dietary intervention may provide a superior option to aspirin possibly via providing an important but less dramatic antiplatelet effect versus aspirin, in addition to a reduced bleeding complications profile. We suggest that our studies support the case for large-scale and long-term clinical studies assessing the therapeutic potential of a dietary nitrate intervention on platelet reactivity in patients at risk of atherothrombotic events.
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![Dietary nitrate supplementation elevates plasma nitrite levels and attenuates platelet reactivity in healthy male volunteers. *Ex vivo* platelet (PRP) aggregation assessed by light transmission aggregometry in response to ADP (0.1--0.3 µmol/L), collagen (0.1--30 µg/ml), and epinephrine (0.001--100 µmol/L), before and 3 h post placebo (A--C) or dietary nitrate (beetroot juice, ∼3.1 mmol nitrate, D--F) (*n*=12). Effect of dietary nitrate on plasma nitrate (G) and nitrite (H) concentrations. Data are expressed as mean±SEM. Significance shown as \#\#\#*P*\<0.001 for two-way repeated-measures ANOVA, and ^⁎^*P*\<0.05,^⁎⁎^*P*\<0.01, and ^⁎⁎⁎^*P*\<0.001 for Bonferroni post hoc tests following one-way or two-way repeated-measures ANOVA as appropriate. (ADP, adenosine diphosphate; PRP, platelet-rich plasma).](gr1){#f0005}

![Dietary nitrate supplementation elevates plasma nitrite levels but does affect platelet reactivity in healthy female volunteers. *Ex vivo* platelet (PRP) aggregation assessed by light transmission aggregometry in response to (A, B) ADP (0.1--0.3 µmol/L), (C, D) collagen (0.1--30 µg/ml), and (E, F) epinephrine (0.001--100 µmol/L), and (G) plasma nitrate and (H) nitrite levels before and 3 h post placebo or dietary nitrate (beetroot juice, ∼3.1 mmol nitrate) consumption in females (*n*=12). Data are expressed as mean±SEM. Significance shown as ^⁎⁎⁎^*P*\<0.001 for Bonferroni post hoc tests following one-way ANOVA. (ADP, adenosine diphosphate; PRP, platelet-rich plasma).](gr2){#f0010}

![Spermine-NONOate but not KNO~2~ inhibits aggregation of platelet-rich plasma (PRP). Platelet aggregation induced by ADP (0.1--0.3 µmol/L) or collagen (0.1--30 µg/ml) assessed by light transmission aggregometry in PRP from healthy untreated male volunteers incubated *ex vivo* for 30 min with either KNO~2~ (A, B) or spermine-NONOate (C, D) or for 10 min with KNO~2~ (1 µmol/L, E, F) or spermine-NONOate (10 µmol/L G, H). Data are expressed as mean±SEM of *n*=5--13. Significance shown as \#*P*\<0.05, \#\#*P*\<0.01, and \#\#\#*P*\<0.001 for two-way repeated-measures ANOVA followed by Bonferroni post tests shown as ^⁎⁎^*P*\<0.01 and ^⁎⁎⁎^ for *P*\<0.001. (ADP, adenosine diphosphate; PRP, platelet-rich plasma; Sper-NO, Spermine-NONOate).](gr3){#f0015}

![KNO~2~ reduces platelet aggregation in whole blood with an associated rise in platelet cGMP in males. Platelet aggregation assessed by impedance aggregometry of whole blood of healthy male volunteers incubated *ex vivo* with KNO~2~ (0.3---3 µmol/L) in response to (A) ADP (10 µmol/L, *n*=13), (B) collagen (3 µg/ml, *n*=11), and (C) epinephrine (10 µmol/L, *n*=11). Platelet cGMP levels in whole blood of males incubated with KNO~2~ (D, 1 µmol/L, *n*=12). Effect of *ex vivo* incubation of whole blood with KNO~2~ (0.3--3 µmol/L) on (E) ADP-induced (10 µmol/L, *n*=7) aggregation and (F) platelet cGMP levels (*n*=6) collected from untreated healthy female volunteers. Data are expressed as mean±SEM. Significance shown as ^⁎^*P*\<0.05, ^⁎⁎^*P*\<0.01 for Dunnett\'s post hoc test compared to control (PBS) following one-way ANOVA. For cGMP data, significance shown as ^⁎^*P*\<0.05 following paired *t* test. White bars represent PBS and black bars nitrite (ADP, adenosine diphosphate).](gr4){#f0020}

![KNO~3~ but not KCl (8 mmol) supplementation elevates systemic nitrate and nitrite levels in healthy male volunteers. The effects of KNO~3~ or KCl ingestion 3 h prior on circulating plasma (A,B), salivary (C,D), and urinary (E,F) nitrate and nitrite levels. Data are expressed as mean±SEM of *n*=12. Significance shown for Bonferroni post hoc tests between groups as ^⁎⁎^*P*\<0.01 and ^⁎⁎⁎^*P*\<0.001 following one-way ANOVA.](gr5){#f0025}

![KNO~3~ but not KCl (8 mmol) supplementation elevates systemic nitrate and nitrite levels in healthy female volunteers. The effects of KNO~3~ or KCl ingestion 3 h prior on circulating plasma (A, B), salivary (C, D), and urinary (E, F) nitrate and nitrite levels. Data are expressed as mean ±SEM of *n*=12. Significance shown for Bonferroni post hoc tests between groups as ^⁎⁎^*P*\<0.01 and ^⁎⁎⁎^*P*\<0.001 following one-way ANOVA.](gr6){#f0030}

![KNO~3~ (8 mmol) supplementation attenuates platelet aggregation in healthy male but not female volunteers. Platelet aggregation assessed by impedance aggregometry of whole blood collected from healthy male volunteers in response to ADP (10 µmol/L) and epinephrine (10 µmol/L) before and 3h post KNO~3~ (A, C) and KCl (B, D) supplementation and female volunteers (E, G and F, H respectively). Data are expressed as mean±SEM of *n*=12. Significance shown for Bonferroni post hoc tests between groups as ^⁎^*P*\<0.05 following one-way ANOVA (ADP, adenosine diphosphate).](gr7){#f0035}

![KNO~3~ supplementation elevates platelet cGMP levels and simultaneously suppresses unstimulated platelet P-selectin expression in healthy male but not female volunteers. Platelet count (A, *n*=12), platelet cGMP levels (B, *n*=9) and platelet P-selectin expression (C and D, *n*=11--12) in healthy males following KNO~3~ or KCl (8 mmol) supplementation and in healthy females (E--H, respectively). Erythrocytic nitrite reductase activity at pH 7.4 (I) and pH 6.8 (J), in males (*n*=7) and females (*n*=5). All data are expressed as mean±SEM. Significance shown as ^⁎^*P*\<0.05 and ^⁎⁎^*P*\<0.01 following paired *t* test for two groups. No significant differences in nitrite reductase activity assessed using two-way repeated-measures ANOVA.](gr8){#f0040}

###### 

Demographics, hemodynamic and plasma NO~*x*~ values for both limbs of the dietary nitrate (beetroot juice) vs low-nitrate-containing water supplementation study.

  Characteristic         Placebo                Dietary Nitrate   *P* value
  ---------------------- ----------- ---------- ----------------- -----------
  Male (*n*)                         12                           
  Age (years)                        26.1±0.8                     
  BMI (kg/m^2^)                      23.8±1.2                     
  Baseline SBP (mm Hg)   126.4±3.9              126.5±3.8         0.98
  Baseline DBP (mm Hg)   71.8±2.8               72.1±1.9          0.87
  Female (*n*)                       12                           
  Age (years)                        24.1±1.9                     
  BMI (kg/m^2^)                      22.9±1.1                     
  Baseline SBP (mm Hg)   106.8±2.3              105.1±1.9         0.26
  Baseline DBP (mm Hg)   64.0±1.6               65.0±1.4          0.39

Statistical analysis conducted using paired *t* test.

###### 

Baseline demographic, hemodynamic, and analytical parameters for both limbs of the potassium nitrate (8 mmmol) versus potassium chloride (8 mmol) capsule study.

  Characteristic         Placebo                Inorganic nitrate   *P* value
  ---------------------- ----------- ---------- ------------------- -----------
  Male (*n*)                         12                             
  Age (years)                        26.7±1.4                       
  BMI (kg/m^2^)                      22.8±2.0                       
  Baseline SBP (mm Hg)   120.3±3.2              121.0±3.7           0.80
  Baseline DBP (mm Hg)   67.2±1.8               66.8±2.0            0.77
  Female (*n*)                       12                             
  Age (years)                        29.3±1.8                       
  BMI (kg/m^2^)                      22.9±0.8                       
  Baseline SBP (mm Hg)   107.8±2.6              106.1±2.3           0.44
  Baseline DBP (mm Hg)   68.8±2.0               67.3±2.2            0.35

Statistical analysis conducted using paired *t* test.

###### 

Effect of the NO donor Spermine NONOate on ADP (10 μmol/L)-induced platelet aggregation in whole blood of male (*n*=5) and female (*n*=5) healthy volunteers.

  Spermine NONOate (μmol/L)   Male (% control ADP response)   Female (% control ADP response)
  --------------------------- ------------------------------- ---------------------------------
  0.1                         117.9±2.6                       107.9±4.6
  1.0                         106.9±4.7                       99.9±4.2
  3.0                         46.9±17.1^⁎⁎^                   75.6±14.6
  10.0                        3.5±2.1^⁎⁎⁎^                    10.0±2.2^⁎⁎⁎^

Data shown as mean±SEM. Statistical significance determined using one-way ANOVA followed by Dunnett\'s comparison to the control response to ADP in each \<respective sex (male aggregation response= 37.0±2.9 and female aggregation= 50.5±1.6).
